ChemicalBook > Product Catalog >API >Antineoplastic agents >Enfortumab Vedotin

Enfortumab Vedotin

Request For Quotation
Enfortumab Vedotin Suppliers list
Company Name: Biolab Reagents  Gold
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com

Enfortumab Vedotin manufacturers

Related articles
Enfortumab Vedotin Basic information
Product Name:Enfortumab Vedotin
Synonyms:Enfortumab Vedotin;Research Grade Enfortumab(DHJ41001);Research Grade Enfortumab;Enfortumab vedotin-ejfv (anti-Nectin-4);Enfortumab
CAS:1346452-25-2
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Enfortumab Vedotin Structure
Enfortumab Vedotin Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Enfortumab Vedotin Usage And Synthesis
UsesEnfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable maleimidocaproylvaline-citrulline linker (SGD-1006). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma[1][2].
SynthesisSynthesis of enfortumab vedotin
Enfortumab Vedotin synthesis
References[1] Halford Z, et al. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother. 2021 Jun;55(6):772-782. DOI:10.1177/1060028020960402
[2] Chang E, et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Feb 15;27(4):922-927. DOI:10.1158/1078-0432.CCR-20-2275
Enfortumab Vedotin Preparation Products And Raw materials
Tag:Enfortumab Vedotin(1346452-25-2) Related Product Information
Durvalumab Denosumab Evolocumab Monalizumab Avelumab Alirocumab Nivolumab Tislelizumab Toripalimab Pembrolizumab